Public Employees Retirement Association of Colorado Has $1.40 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Public Employees Retirement Association of Colorado trimmed its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 26.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,734 shares of the company's stock after selling 11,971 shares during the quarter. Public Employees Retirement Association of Colorado's holdings in Moderna were worth $1,403,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its holdings in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc purchased a new position in Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the period. Crowley Wealth Management Inc. purchased a new stake in Moderna in the 4th quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Up 2.1 %

Shares of MRNA stock traded up $0.58 during trading hours on Friday, reaching $27.61. 7,542,573 shares of the company's stock were exchanged, compared to its average volume of 7,424,082. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock has a market capitalization of $10.67 billion, a P/E ratio of -2.98 and a beta of 1.99. The business has a fifty day moving average price of $29.52 and a 200-day moving average price of $37.46.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.07) EPS. As a group, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and reduced their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Citigroup began coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective on the stock. Finally, Evercore ISI reduced their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.